UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort

International journal of cancer, 2022-10, Vol.151 (8), p.1355-1366

2022

Volltextzugriff (PDF)

Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade

Scientific reports, 2021-05, Vol.11 (1), p.10843-10843, Article 10843

2021

Volltextzugriff (PDF)

No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer

British journal of cancer, 2022-04, Vol.126 (6), p.881-888

2022

Volltextzugriff (PDF)

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis

Breast cancer research and treatment, 2018-06, Vol.169 (3), p.413-425

2018

Volltextzugriff (PDF)

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer

Future oncology (London, England), 2017-12, Vol.13 (30), p.2733-2736

2017

Volltextzugriff (PDF)

Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy

Radiology and oncology, 2023-06, Vol.57 (2), p.220-228

2023

Volltextzugriff (PDF)

BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome

Breast cancer (Tokyo, Japan), 2022-09, Vol.29 (5), p.921-927

2022

Volltextzugriff (PDF)

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis

JNCI cancer spectrum, 2019-06, Vol.3 (2), p.pkz033

2019

Volltextzugriff (PDF)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

Current oncology (Toronto), 2020-12, Vol.28 (1), p.107-114

2020

Volltextzugriff (PDF)

Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors

Cancer medicine (Malden, MA), 2020-11, Vol.9 (21), p.7888-7895

2020

Volltextzugriff (PDF)

Targeting CDK4/6 pathways and beyond in breast cancer

Breast (Edinburgh), 2019-02, Vol.43, p.8-17

2019

Volltextzugriff (PDF)

Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis

JNCI : Journal of the National Cancer Institute, 2018-01, Vol.110 (1), p.31-39

2018

Volltextzugriff (PDF)

Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2021-11, Vol.113 (11), p.1465-1475

2021

Volltextzugriff (PDF)

Prognostic role of the stromal tumor-infiltrating lymphocytes (TILs) in women with early ER+/HER2+ breast cancer (BC) in whom adjuvant chemotherapy (ChT) was omitted

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e12526-e12526

2022

Volltextzugriff (PDF)

Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12501-e12501

2018

Volltextzugriff (PDF)

Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?

American Society of Clinical Oncology educational book, 2016, Vol.36 (36), p.e31-e38

2016

Volltextzugriff (PDF)

Extended adjuvant endocrine therapy – A standard to all or some?

Breast (Edinburgh), 2017-04, Vol.32, p.112-118

2017

Volltextzugriff (PDF)

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis

Cancer treatment reviews, 2018-12, Vol.71, p.68-75

2018

Volltextzugriff (PDF)

Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer

Clinical breast cancer, 2020-12, Vol.20 (6), p.495-502

2020

Volltextzugriff (PDF)

2888: Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients

Radiotherapy and oncology, 2024-05, Vol.194, p.S691-S692

2024

Volltextzugriff (PDF)

Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy

Cancer treatment reviews, 2018-11, Vol.70, p.138-143

2018

Volltextzugriff (PDF)

Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer

Radiotherapy and oncology, 2022-12, Vol.177, p.40-45

2022

Volltextzugriff (PDF)

Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19206-e19206

2020

Volltextzugriff (PDF)

Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis

Cancer treatment reviews, 2017-11, Vol.60, p.53-59

2017

Volltextzugriff (PDF)

Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.6588-6588

2018

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort

Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade

No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer

Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy

BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors

Targeting CDK4/6 pathways and beyond in breast cancer

Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis

Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis

Prognostic role of the stromal tumor-infiltrating lymphocytes (TILs) in women with early ER+/HER2+ breast cancer (BC) in whom adjuvant chemotherapy (ChT) was omitted

Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis

Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?

Extended adjuvant endocrine therapy – A standard to all or some?

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis

Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer

2888: Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients

Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy

Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer

Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors

Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis

Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade

Suchergebnisse filtern